Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2008 21:52 ET | Source: Biota Holdings

LANI Phase II Completed -- Phase III Scheduled

MELBOURNE, AUSTRALIA--(Marketwire - July 30, 2008) - Biota Holdings Limited (ASX: BTA) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial...
July 30, 2008 08:21 ET | Source: Novogen, Limited

Novogen Raises A$5.5m for Investment in Marshall Edwards

SYDNEY, AUSTRALIA--(Marketwire - July 30, 2008) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has raised A$5.5million in an equity issue to substantial shareholder El Coronado Holdings LLC at A$1.22...
July 30, 2008 08:15 ET | Source: Marshall Edwards, Inc.

Marshall Edwards, Inc. Raises $10,000,000 in Public Offering

WASHINGTON, DC and SYDNEY, AUSTRALIA--(Marketwire - July 30, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced today that it entered into a Securities Subscription Agreement with Novogen...
July 21, 2008 09:57 ET | Source: Biota Holdings Limited

Biota and GSK Conclude Litigation Through Mediation

MELBOURNE, AUSTRALIA--(Marketwire - July 21, 2008) - Biota Holdings Limited (ASX: BTA) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal...
June 26, 2008 08:09 ET | Source: Marshall Edwards, Inc.

Marshall Edwards, Inc. Joins Russell 3000(R) Index

NEW CANAAN, CT--(Marketwire - June 26, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL), a clinical-stage biotechnology company developing a new class of oncology drugs known as "multi-signal...
June 23, 2008 08:00 ET | Source: Novogen, Limited

Novogen Signs Spanish Patent License With Laboratorios Casen-Fleet

STAMFORD, CT and SYDNEY, AUSTRALIA--(Marketwire - June 23, 2008) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN), the registered owner of the European Patent "Use of isoflavone phyto-oestrogen extracts...
June 18, 2008 17:06 ET | Source: International Regulome Consortium

Invitrogen Partners With International Regulome Consortium to Advance Stem Cell Research for the Development of Life Saving Therapies

SAN DIEGO, CA--(Marketwire - June 18, 2008) - The International Regulome Consortium (IRC) announced today it has signed a non-binding letter of intent with Invitrogen Corporation (NASDAQ: IVGN) to...
June 09, 2008 08:00 ET | Source: Marshall Edwards, Inc.

Independent Data Monitoring Committee Recommends Marshall Edwards, Inc.'s OVATURE Trial Continue

NEW CANAAN, CT--(Marketwire - June 9, 2008) - The Independent Data Monitoring Committee (IDMC) constituted to oversee the conduct of the Phase III OVArian TUmor REsponse (OVATURE) Trial, has...
May 15, 2008 21:00 ET | Source: Marshall Edwards, Inc.

Clinical Phase I Study Report of Marshall Edwards' Compound Triphendiol to Be Reported in ASCO Proceedings

NEW CANAAN, CT--(Marketwire - May 15, 2008) - An abstract submitted to the Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, Chicago, Illinois, entitled "Phase Ia...
May 09, 2008 08:29 ET | Source: Marshall Edwards, Inc.

Extended Accrual Time and Decreased Sample Size for OVATURE, a Multinational Phase III Clinical Study for Women With Recurrent Ovarian Cancer

SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - May 9, 2008) - The accrual time for the OVArian TUmor REsponse (OVATURE) clinical study, a Phase III study of the investigational...